|
Andrew M. Green became a director of the Company on July 26, 2006, upon
the merger with JDA. On June 25, 2007, he was appointed as Chief Executive
Officer and President. He had been a consultant to JDA from May 2006 until the
merger. Previously, since June 2005, he was a principal in NeoMedica, LLC, a
consulting group that specialized in executive level medical device consulting
for clients that included early stage ventures dealing with Class III devices
involving cardiology, ophthalmology, orthopedics, and electrophysiology. Prior
to that, from 1996 until 2005, he was employed by the Novoste Corporation (a
publicly traded medical device company). His final position with Novoste was as
a corporate officer with responsibility for Regulatory Affairs, Clinical
Affairs, Quality Assurance and New Technology/Business Development. From 1993
until his employment with Novoste, he was employed as a Scientific
Reviewer/Biomedical Engineer for the FDA, where he was responsible for the
review of scientific, technical, pre-clinical and clinical data submitted in
support of the safety and effectiveness of both interventional and general
cardiovascular devices. He holds a BS degree in Biological Sciences and an MS
degree in Bioengineering, both from Clemson University, where his research
focused on characterization and use of materials in a biological environment. | 